Transcatheter Aortic Valve Replacement in Failed Transcatheter Bioprosthetic Valves

Transcatheter aortic valve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients. Given the longer life expectancy of these patients, the bioprosthetic valve will eventually fail, and aortic valve reintervention may be necessary. Although currently rare, redo-TAVR wilt likely increase in the future as younger patients are expected to outlive their transcatheter bioprosthesis. This review provides a contemporary overview of the indications, procedural planning, implantation technique, and outcomes of TAVR in failed transcatheter bioprosthetic aortic valves. (C) 2022 by the American College of Cardiology Foundation.

Automated summary

The article discusses the increasing use of TAVR in younger and lower surgical risk patients and the potential need for redo-TAVR in the future due to the longer life expectancy of these patients. It provides an overview of indications, procedural planning, implantation technique, and outcomes in failed transcatheter bioprosthetic aortic valves.